期刊文献+

肠道病毒71型与脊髓灰质炎病毒抗体交叉反应性研究 被引量:1

Cross-reactivity between anti-enterovirus 71 and anti-pliovirus antibodies
原文传递
导出
摘要 通过临床血清样本研究及实验动物验证,探讨肠道病毒71型(EV71)与脊髓灰质炎病毒(PV)之间的抗体交叉反应性。以酶联免疫吸附试验(ELISA)分别检测健康儿童血清中IgG型抗体与EV71及PV的反应性;用原核表达与亲和纯化等方法分别获得EV71和PV的衣壳蛋白VP1及非结构蛋白3C;将PV-VP1、EV71-VP1、EV71灭活疫苗及PV灭活疫苗(IPV)分别经皮下免疫BALB/c小鼠制得免疫血清,以蛋白免疫印迹实验分别研究PV-VP1或EV71-VP1小鼠阳性血清与EV71-VP1和PV-VP1的反应情况,进一步以竞争ELISA试验分别研究EV71-VP1对PV-VP1与其特异性免疫血清特异结合的影响。微量中和试验研究PV阳性抗血清对EV71的体外中和效应。结果:已接种PV疫苗但未曾感染EV71的健康儿童的IgG抗体与EV71有较高的反应性,且针对EV71及PV两种病毒的IgG抗体的相对含量成正相关;蛋白免疫印迹实验显示PV-VP1与EV71-VP1免疫的小鼠抗血清中存在交叉抗体,竞争ELISA试验进一步表明EV71-VP1蛋白能明显抑制PV-VP1与其特异性免疫血清抗体的结合,反之亦然。但中和实验揭示PV阳性血清在体外不能中和EV71病毒。PV之间存在大量交叉反应性抗体,但PV免疫后产生的与EV71交叉反应的抗体是非中和性质抗体。非中和抗体可能通过免疫调理效应在EV71病毒的致病的过程中发挥重要作用。 The aim of this study was to investigate the cross-reactivity between the antibodies against enterovirus 71(EV71) and poliovirus(PV).Reactivity of the two viruses to IgG antibodies specific to EV71 or PV in serum samples from children were tested respectively using ELISA assay;neutralizating effect of PV-seropositive human serum against EV71 was detected with microtiter neutralization assay;VP1 and 3C proteins were expressed in E.coli and purified with affinity purification.Antisera were prepared from the BALB/c mice immunized subcutaneously with PV-VP1,formalin-inactivated EV71 and PV vaccine.Reactivity of anti-serum of PV-VP1(or EV71-VP1) to EV71-VP1(or PV-VP1) and inhibitory effect of EV71-VP1 on the binding of PV-VP1 to its specific IgG were investigated by Western blot and ELISA assay,respectively.The sera of healthy children who has immunized by OPV but not infected by EV71 display high reactivity to EV71 and the levels of EV71-specific and PV-specific antibodies in serum samples of EV71-seronegative children correlate well with each other.In addition,ELISA assay shows EV71 VP1 protein has a marked inhibition effect on the binding of PV VP1 to specific IgG antibodies,and vice versa.The cross-reactivity was also demonstrated in a Western blot assay with anti-sera made from PV-VP1-immunized mice.However,the antibodies against PV do not have crossreactive neutralizing activity against EV71.In conclusion,PV immunization elicits cross-reactive,non-neutralizing antibodies against EV71.These cross-reactive antibodies may play an important role in pathogenesis of EV71 infection through opsonization.
出处 《现代免疫学》 CAS CSCD 北大核心 2012年第3期187-192,共6页 Current Immunology
基金 国家自然科学资金面上项目(81172807)
关键词 肠道病毒71型 脊髓灰质炎病毒 交叉反应性抗体 enterovirus 71 poliovirus cross-reactive antibody
  • 相关文献

参考文献21

  • 1Zhu Z, Zhu S, Guo X, et al. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large- scale outbreaks from 2008[J]. Virol J, 2010,7: 300-306.
  • 2McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance[J]. FEMS Mi- erobiol Rev, 2002,26:91-107.
  • 3Liua CC, Choua AH, Lien SP. Identification and character- ization of a cross-neutralization epitope of Enterovirus 71[J]. Vaecine, 2011,29:4362-4372.
  • 4Orjan. Strannegard CJ, Svennerholm B. A study of the cellular immune response to enteroviruses in humans: Identifica- tion of cross-reactive T cell epitopes on the structural proteins of enteroviruses[J]. J Gen Virol, 1996,77:2097-2108.
  • 5Samuelson A, Forsgren M, Johansson B, et al. Molecular basis for serological cross-reactivity between Enteroviruses [J]. Clin Diag Lab Immunol, 1994,1:336-341.
  • 6赵俊杰,付承英.CpG ODN生物学活性和免疫作用的研究进展[J].现代免疫学,2011,31(2):168-171. 被引量:6
  • 7熊思东.抗病毒感染的固有免疫机制[J].现代免疫学,2011,31(3):179-180. 被引量:9
  • 8王媛媛,韩红辉,杜冰,钱旻.一种新型肝癌免疫毒素的表达、纯化及初步鉴定[J].现代免疫学,2008,28(2):110-115. 被引量:11
  • 9Rabenau HF, Richter M, Doerr HW. Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany[J]. Med Microbiol Immunuol, 2010,199 : 45-51.
  • 10王金德,许以平,曹玲仙,姚苏杭.黑胸大蠊与美洲大蠊交叉抗原成分比较[J].上海免疫学杂志,2000,20(5):295-297. 被引量:6

二级参考文献50

  • 1胡向农,魏强.CpG ODN诱导浆细胞样树突状细胞免疫调节的作用机制[J].现代免疫学,2005,25(4):337-340. 被引量:3
  • 2吴淼,杜冰,汪磊,周忠良,钱旻,于静.肝癌特异性黏附肽的鉴定和分析[J].现代免疫学,2006,26(2):143-146. 被引量:2
  • 3[1]Schwartz M,Roayaie S,Konstadoulakis M.Strategies for the management of hepatocellular carcinoma[J].Nat Clin Pract Oncol,2007,4(7):424-432.
  • 4[2]Pastan I,Hassan R,FitzGerald DJ,et al.Immunotoxin treatment of cancer[J].Annu Rev Med,2007,58:221-237.
  • 5[5]Du B,Qian M,Zhou Z,et al.In vitro panning of a targeting peptide to hepatocarcinoma from a phage display peptide library[J].Biochem Biophys Res Commun,2006,342(3):956-962.
  • 6[6]Wu M,Du B,Wang L,et al.A Liver-tumor adhere peptide from the phage radom peptide library[J].Chin Cancer Res,2006,18(4):241-245.
  • 7[7]Park SC,Kim JY,Shin SO,et al.Investigation of toroidal pore and oligomerization by melittin using transmission electron microscopy[J].Biochem Biophys Res Commun,2006,343(1):222-228.
  • 8[8]Son DJ,Lee JW,Lee YH,et al.Therapeutic application of anti-arthritis,pain-releasing,and anti-cancer effects of bee venom and its constituent compounds[J].Pharmacol Ther,2007,115(2):246-270.
  • 9[9]Chu ST,Cheng HH,Huang CJ,et al.Phospholipase A2-independent Ca2+entry and subsequent apoptosis induced by melittin in human MG63 osteosarcoma cells[J].Life Sci,2007,80(4):364-369.
  • 10[10]Werkmeister JA,Kirkpatrick A,McKenzie JA,et al.The effect of sequence variations and structure on the cytolytic activity of melittin peptides[J].Biochim Biophys Acta,1993,1157(1):50-54.

共引文献29

同被引文献15

  • 1岳艳,徐薇,蒋正刚,胡林昆,李康,熊思东.C家族趋化因子XCL1增强CVB3基因疫苗的抗病毒免疫应答及保护作用[J].现代免疫学,2008,28(2):91-95. 被引量:9
  • 2Esfancliarei M, Mcmanus BM. Molecular biology and patho- genesis of viral myocarditis[J]. Ann Rev Pathol, 2008, 3:127-155.
  • 3Kim DS, Nam JH. Characterization of attenuated coxsack- ievirus B3 strains and prospects of their application as live-at- tenuated vaccines[J]. Expert Opin Biol Ther, 2010, 10: 179- 190.
  • 4Tsetsarkin KA, Liu G, Shen K, et al. Kissing-loop interac- tion between 5' and 3' ends of tick-borne Langat virus genome "bridges the gap' between mosquito- and tick-borne flaviviruses in mechanisms of viral RNA cyclization: applications for virus attenuation and vaccine development[J]. Nuc Acids Res, 2016[Epub ahead of print], http://nar, oxfordjournals, org/ content/early/2016/02/04/nar, gkw061, long.
  • 5Barnes D, Kunitomi M, Vignuzzi M, et al. Harnessing en- dogenous miRNAs to control virus tissue tropism as a strate- gy for developing attenuated virus vaccines[J]. Cell Host Mi- crobe, 2008, 4:239-248.
  • 6Kelly EJ, Hadac EM, Cullen BR, et al. MicroRNA antago- nism of the picornaviral life cycle: alternative mechanisms of interference[J]. PLoS Pathog, 2010, 6: e1000820.
  • 7He F, Yao H, Wang J, et al. Coxsackievirus B3 engineered to contain microRNA targets for muscle-specific microRNAs displays attenuated cardiotropic virulence in mice[J]. J Virol, 2015, 89:908-916.
  • 8Liu Z, Carthy CM, Cheung P, etal. Structural and function- al analysis of the 5' untranslated region of coxsackievirus B3 RNA: In vivo translational and infectivity studies of full- length mutants[J]. Virology, 1999, 265: 206-217.
  • 9He F, Yao H, Xiao Z, etal. Inhibition of II.-2 inducible T- cell kinase alleviates T-cell activation and murine myocardial inflammation associated with CVB3 infection[J]. Mol Immu- nol, 2014, 59: 30-38.
  • 10Yao H, Zhang Y, He F, et al. Short hairpin RNA targeting 2B gene of coxsackievirus B3 exhibits potential antiviral effects both in vitro and in vivo[J]. BMC Infect Dis, 2012, 12: 177.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部